Phase Ia study of SYNT001 in healthy volunteers

Trial Profile

Phase Ia study of SYNT001 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Syntimmune
  • Most Recent Events

    • 28 Mar 2016 New trial record
    • 22 Mar 2016 According to Syntimmune media release, company intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of this study later in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top